Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Wilder-Smith, Annelies [VerfasserIn]   i
 Smith, Peter Geoffrey [VerfasserIn]   i
 Luo, R. [VerfasserIn]   i
 Kelly-Cirino, C. [VerfasserIn]   i
 Curry, D. [VerfasserIn]   i
 Larson, Heidi [VerfasserIn]   i
 Durbin, Anna P. [VerfasserIn]   i
 Chu, M. [VerfasserIn]   i
 Tharmaphornpilas, P. [VerfasserIn]   i
 Ng, L. C. [VerfasserIn]   i
 Sartori, A. M. C. [VerfasserIn]   i
 Luna, E. J. A. [VerfasserIn]   i
 Gubler, Duane J. [VerfasserIn]   i
 España, G. [VerfasserIn]   i
 Yoon, I. K. [VerfasserIn]   i
 Flasche, S. [VerfasserIn]   i
Titel:Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine
Titelzusatz:a meeting report
Verf.angabe:A. Wilder-Smith, P.G. Smith, R. Luo, C. Kelly-Cirino, D. Curry, H. Larson, A. Durbin, M. Chu, P. Tharmaphornpilas, L.C. Ng, A.M.C. Sartori, E.J.A. Luna, D.J. Gubler, G. España, I.K. Yoon, S. Flasche
E-Jahr:2019
Jahr:31 July 2019
Umfang:10 S.
Fussnoten:Gesehen am 21.04.2020
Titel Quelle:Enthalten in: Vaccine
Ort Quelle:Amsterdam : Elsevier, 1983
Jahr Quelle:2019
Band/Heft Quelle:37(2019), 36, Seite 5137-5146
ISSN Quelle:1873-2518
Abstract:The first licensed dengue vaccine, CYD-TDV (Dengvaxia) is efficacious in seropositive individuals, but increases the risk for severe dengue in seronegative persons about two years after administration of the first dose. For countries considering the introduction of Dengvaxia, WHO recommends a pre-vaccination screening strategy whereby only persons with evidence of a past dengue infection would be vaccinated. Policy-makers need to consider the risk-benefit of vaccination strategies based on such screening tests, the optimal age to introduce the vaccine, communication and implementation strategies. To address these questions, the Global Dengue and Aedes-transmitted diseases Consortium (GDAC) organized a 3-day workshop in January 2019 with country representatives from Asia and Latin America. The meeting discussions highlighted many challenges in introducing Dengvaxia, in terms of screening test characteristics, costs of such tests combined with a 3-dose schedule, logistics, achieving high coverage rates, vaccine confidence and communication; more challenges than for any other vaccine introduction programme. A screening test would require a high specificity to minimize individual risk, and at the same time high sensitivity to maximize individual and population benefit. The underlying seroprevalence dependent positive predictive value is the best indicator for an acceptable safety profile of a pre-vaccination screening strategy. The working groups discussed many possible implementation strategies. Addressing the bottlenecks in school-based vaccine introduction for Dengvaxia will also benefit other vaccines such as HPV and booster doses for tetanus and pertussis. Levels of public trust are highly variable and context specific, and understanding of population perceptions and concerns is essential to tailor interventions, monitor and mitigate risks.
DOI:doi:10.1016/j.vaccine.2019.07.016
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.vaccine.2019.07.016
 Volltext: http://www.sciencedirect.com/science/article/pii/S0264410X19308941
 DOI: https://doi.org/10.1016/j.vaccine.2019.07.016
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Brazil
 Communication
 Dengue
 Ethics
 National vaccination programmes
 Philippines
 Rapid diagnostic tests
 Vaccine hesitancy
 WHO
K10plus-PPN:1695568397
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68568834   QR-Code
zum Seitenanfang